JP Morgan Chase
RARE icon

JP Morgan Chase’s Ultragenyx Pharmaceutical RARE Stock Holding History

JP Morgan Chase’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-90,800
Closed -$2.09M – 7823
2025
Q4 		$2.09M Buy
90,800
+87,300
+2,494% +$2.87M ﹤0.01% 4033
2025
Q3 		$105K Buy
+3,500
New +$105K ﹤0.01% 5874
2025
Q2 		– Sell
-51,000
Closed -$1.85M – 7539
2025
Q1 		$1.85M Buy
51,000
+21,000
+70% +$874K ﹤0.01% 3942
2024
Q4 		$1.26M Buy
+30,000
New +$1.49M ﹤0.01% 4460
2024
Q3 		– Sell
-35,000
Closed -$1.44M – 7627
2024
Q2 		$1.44M Hold
35,000
– – ﹤0.01% 4019
2024
Q1 		$1.63M Buy
+35,000
New +$1.65M ﹤0.01% 4001
2019
Q3 		– Sell
-16,700
Closed -$1.04M – 5915
2019
Q2 		$1.04M Sell
16,700
-60,000
-78% -$3.82M ﹤0.01% 3847
2019
Q1 		$5.32M Buy
+76,700
New +$4.38M ﹤0.01% 2540
2018
Q3 		– Sell
-30,000
Closed -$2.31M – 5789
2018
Q2 		$2.31M Buy
+30,000
New +$1.94M ﹤0.01% 3311

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase's RARE Position: Q1 2026 in Review

JP Morgan Chase reduced its Ultragenyx Pharmaceutical (RARE) stake by 94% in Q1 2026, selling an estimated $84M and leaving 245,928 shares worth $4.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3358.

JP Morgan Chase first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $121M in Q3 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • JP Morgan Chase held 245,928 shares of Ultragenyx Pharmaceutical worth $4.75M as of Q1 2026.
  • JP Morgan Chase sold 3,728,102 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $84M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3358 holding.
  • JP Morgan Chase first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
  • JP Morgan Chase's Ultragenyx Pharmaceutical position peaked at $121M in Q3 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.